Hormonal
Disruption of cardiolipin synthesis in thermogenic fat leads to insulin resistance and reduced metabolic flexibility through a mechanism involving ER stress factor CHOP-10.
This finding highlights that brown fat health is not just about burning calories but also about signaling. Disrupting this signaling (via lack of cardiolipin) can lead to insulin resistance. This suggests that preserving brown fat function through lifestyle factors like cold exposure might help maintain insulin sensitivity.
Cardiolipin depletion in brown and beige fat abolishes adipose thermogenesis and glucose uptake, which renders animals insulin resistant... CL depletion globally decreased oxidative phosphorylation and other mitochondrial gene programs... mediated through the ER stress response factor, CHOP-10.
Why this rating
Clear mechanistic pathway identified in mouse models with supporting human genetic data.
Source
Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis
Elahu G. Sustarsic et al. · Cell Metabolism · 2018
DOI 10.1016/j.cmet.2018.05.003
More from this paper
- Synthesis of the mitochondrial phospholipid cardiolipin (CL) in brown and beige fat is essential for systemic energy homeostasis, insulin sensitivity, and metabolic flexibility.Good
- Higher expression of the cardiolipin synthase gene CRLS1 in human subcutaneous adipose tissue is positively correlated with insulin sensitivity and negatively correlated with insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →